Literature DB >> 11926080

Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.

J D Vanderkooy1, Sidney H Kennedy, R Michael Bagby.   

Abstract

OBJECTIVE: There is no commonly accepted standard for comparing antidepressant-induced side effects. This study evaluates a clinician-administered scale, the Toronto Side Effect Scale (TSES), in a natural practice clinic.
METHOD: We used the TSES to assess side effects in 193 depression patients who completed 8 weeks of treatment with either bupropion, moclobemide, paroxetine, sertraline, or venlafaxine.
RESULTS: Rates of remission (Hamilton Rating Scale for Depression [HRSD] < 7) did not differ across drugs after 8 weeks of treatment. Paired drug comparisons yielded significant differences in 16 of the 32 side effects. We present differences between pairs of the 5 antidepressants in Central Nervous System (CNS), gastrointestinal (GI), and sexual side effects. A measure of side-effect intensity distinguished paroxetine from the other antidepressants on a measure of sexual dysfunction.
CONCLUSIONS: These results confirm the clinical utility of the TSES as a simple, clinician-administered antidepressant side-effect scale.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11926080     DOI: 10.1177/070674370204700208

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  27 in total

Review 1.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

2.  Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.

Authors:  William W Stoops; Paul E A Glaser; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2013-02-21       Impact factor: 4.530

3.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

4.  Paroxetine-induced reduction of sexual incentive motivation in female rats is not modified by 5-HT1B or 5-HT2C antagonists.

Authors:  Helge Kaspersen; Anders Agmo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-10       Impact factor: 4.530

5.  The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial.

Authors:  Jieun Lee; Sung Joon Cho; Kang Soo Lee; Keunyoung Yook; Ah Young Choe; Sungjae Lee; Borah Kim; Keung-Hyang Kim; Tae Kyou Choi; Sang-Hyuk Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

6.  Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial.

Authors:  Susan D Reed; Caroline M Mitchell; Hadine Joffe; Lee Cohen; Jan L Shifren; Katherine M Newton; Ellen W Freeman; Joseph C Larson; JoAnn E Manson; Andrea Z LaCroix; Katherine A Guthrie
Journal:  Obstet Gynecol       Date:  2014-08       Impact factor: 7.623

7.  Agomelatine and its therapeutic potential in the depressed patient.

Authors:  Sidney H Kennedy; Beata S Eisfeld
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

8.  GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol.

Authors:  Laura Thomas; Jean Mulligan; Victoria Mason; Debbie Tallon; Nicola Wiles; Philip Cowen; David Nutt; Michael O'Donovan; Deborah Sharp; Tim Peters; Glyn Lewis
Journal:  Trials       Date:  2008-05-22       Impact factor: 2.279

9.  Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).

Authors:  R Hamish McAllister-Williams; Eleanor Smith; Ian M Anderson; Jane Barnes; Peter Gallagher; Heinz C R Grunze; Peter M Haddad; Allan O House; Tom Hughes; Adrian J Lloyd; Elaine M M McColl; Simon H S Pearce; Najma Siddiqi; Baxi Sinha; Chris Speed; I Nick Steen; June Wainright; Stuart Watson; Fiona H Winter; I Nicol Ferrier
Journal:  BMC Psychiatry       Date:  2013-08-03       Impact factor: 3.630

10.  The acute side effects of bright light therapy: a placebo-controlled investigation.

Authors:  Yevgeny Botanov; Stephen S Ilardi
Journal:  PLoS One       Date:  2013-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.